entertainment -WSS

entertainment

author：knowledge 2025-10-01 14:20:30 - browse：59

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Assistant physicians can help address the primary care shortage

entertainment

Wikipedia

WSS

Senate bill would ban some hospital facility fees

State of the Union pitch: Bigger Medicare drug price negotiations

FDA weighs limits of animal data in assessing artificial wombs

A new approach to psychiatric drug development

FDA weighs limits of animal data in assessing artificial wombs

A new approach to psychiatric drug development

Wikipedia

entertainment

explore

In age of alternative facts, a scholarly course on calling out crap

Transgender sports debate: Physicians say bans are health issue

Trump demands the U.S. pay no more for drugs than other countries … again

$1 billion proposal to grow Boston, Massachusetts biotech

Walensky prepares to leave CDC — and Congress — behind

Chamber of Commerce, DOJ clash in court over drug prices

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare drug price negotiation hearing pits pharma v Biden admin

Hepatitis C has a cure — but many Americans still lack access to it

Medicare to pay more for cardiac rehab in hospital outpatient clinics

leisure time

'A game

Why the drug industry's warnings on the IRA's impact fall short

Assistant physicians can help address the primary care shortage

Harvard's David Sinclair gets blowback over aging

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Longer MASH drug regimen improved liver, Akero study finds

entertainment

Wikipedia

entertainment

focus